<?xml version='1.0' encoding='utf-8'?>
<document id="27499331"><sentence text="Clinical disposition, metabolism and in vitro drug-drug interaction properties of omadacycline."><entity charOffset="82-94" id="DDI-PubMed.27499331.s1.e0" text="omadacycline" /></sentence><sentence text="1" /><sentence text=" Absorption, distribution, metabolism, transport and elimination properties of omadacycline, an aminomethylcycline antibiotic, were investigated in vitro and in a study in healthy male subjects"><entity charOffset="79-91" id="DDI-PubMed.27499331.s3.e0" text="omadacycline" /><entity charOffset="96-114" id="DDI-PubMed.27499331.s3.e1" text="aminomethylcycline" /><pair ddi="false" e1="DDI-PubMed.27499331.s3.e0" e2="DDI-PubMed.27499331.s3.e0" /><pair ddi="false" e1="DDI-PubMed.27499331.s3.e0" e2="DDI-PubMed.27499331.s3.e1" /></sentence><sentence text=" 2" /><sentence text=" Omadacycline was metabolically stable in human liver microsomes and hepatocytes and did not inhibit or induce any of the nine cytochrome P450 or five transporters tested"><entity charOffset="0-13" id="DDI-PubMed.27499331.s5.e0" text=" Omadacycline" /></sentence><sentence text=" Omadacycline was a substrate of P-glycoprotein, but not of the other transporters"><entity charOffset="1-13" id="DDI-PubMed.27499331.s6.e0" text="Omadacycline" /></sentence><sentence text=" 3" /><sentence text=" Omadacycline metabolic stability was confirmed in six healthy male subjects who received a single 300 mg oral dose of [14C]-omadacycline (36"><entity charOffset="0-13" id="DDI-PubMed.27499331.s8.e0" text=" Omadacycline" /><entity charOffset="119-137" id="DDI-PubMed.27499331.s8.e1" text="[14C]-omadacycline" /><pair ddi="false" e1="DDI-PubMed.27499331.s8.e0" e2="DDI-PubMed.27499331.s8.e0" /><pair ddi="false" e1="DDI-PubMed.27499331.s8.e0" e2="DDI-PubMed.27499331.s8.e1" /></sentence><sentence text="6 μCi)" /><sentence text=" Absorption was rapid with peak radioactivity (∼610 ngEq/mL) between 1-4 h in plasma or blood" /><sentence text=" The AUClast of plasma radioactivity (only quantifiable to 8 h due to low radioactivity) was 3096 ngEq h/mL and apparent terminal half-life was 11" /><sentence text="1 h" /><sentence text=" Unchanged omadacycline reached peak plasma concentrations (∼563 ng/mL) between 1-4 h"><entity charOffset="11-23" id="DDI-PubMed.27499331.s13.e0" text="omadacycline" /></sentence><sentence text=" Apparent plasma half-life was 17" /><sentence text="6 h with biphasic elimination" /><sentence text=" Plasma exposure (AUCinf) averaged 9418 ng h/mL, with high clearance (CL/F, 32" /><sentence text="8 L/h) and volume of distribution (Vz/F 828 L)" /><sentence text=" No plasma metabolites were observed" /><sentence text=" 4" /><sentence text=" Radioactivity recovery of the administered dose in excreta was complete (&gt;95%); renal and fecal elimination were 14" /><sentence text="4% and 81" /><sentence text="1%, respectively" /><sentence text=" No metabolites were observed in urine or feces, only the omadacycline C4-epimer"><entity charOffset="58-70" id="DDI-PubMed.27499331.s23.e0" text="omadacycline" /></sentence><sentence text="" /></document>